Western Blot: GPIHBP1 Antibody [NB110-41537] - (1) Detection of GPIHBP1in transfected lysate and (2) empty vector lysate was used as a negative control.
Immunocytochemistry/ Immunofluorescence: GPIHBP1 Antibody [NB110-41537] - GPIHBP1 antibody was tested in A431 cells with FITC (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).
Immunohistochemistry-Paraffin: GPIHBP1 Antibody [NB110-41537] - Analysis of FFPE mouse skeletal muscle using GPIHBP1 antibody at 1:50 on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat ...read more
Use in Immunohistochemistry-Paraffin reported in scientific literature (PMID: 24735886). Use in chromatin immunoprecipitation reported in scientific literature (PMID: 28099936). Use in FLOW cell surface reported in scientific literature (PMID: 24735886).
Rat and Bovine reactivity reported in scientific literature (PMID: 24735886). Human reactivity reported in scientific literature (PMID: 28099936).
Packaging, Storage & Formulations
Aliquot and store at -20C or -80C. Avoid freeze-thaw cycles.
Tris-Glycine and 0.15M NaCl
0.05% Sodium Azide
Immunogen affinity purified
Alternate Names for GPIHBP1 Antibody
glycosylphosphatidylinositol anchored high density lipoprotein binding protein1
glycosylphosphatidylinositol-anchored high density lipoprotein-binding protein1
GPI anchored high density lipoprotein binding protein 1
GPI-Anchored HDL-Binding Protein 1
High density lipoprotein-binding protein 1
GPIHBP1 (glycosylphosphatidylinositol-anchored HDL-binding protein 1) is a glycosylphosphatidylinositol-anchored glycoprotein of capillary endothelial cells that shuttle lipoprotein lipase (LPL) from the interstitial spaces to capillary lumen, and is essential for triglyceride-rich lipoproteins metabolism in mammalian plasma. GPIHBP1 is localized on luminal/abluminal capillary endothelial cell surfaces where it is bound by a glycosylphosphatidylinositol anchor and associates strongly with LPL. It serves as LPL transporter from sub-endothelial spaces to luminal face of capillaries, enabling lipolysis of circulating triglycerides localized within plasma chylomicrons. It has high affinity for HDL and binds to LPL, chylomicrons as well as APOA5. In the absence of GPIHBP1, the stores of catalytically active LPL within tissues are normal, but the LPL is mislocalized to interstitial spaces and is absent from capillary lumen. LPL mislocalization interferes with lipoprotein lipolysis and causes chylomicronemia. In humans, loss of function GPIHBP1 mutations leads to familial chylomicronemia. It binds LPL and apoA-V strongly for serving as a platform for lipolysis within capillaries, particularly in tissues which show high expression levels for both GPIHBP1 and LPL genes, such as heart, skeletal muscle and adipose tissue. Gpihbp1-/Gpihbp1- knock out mice have shown that GPIHBP1-deficiency causes severe hypertriglyceridemia.
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our GPIHBP1 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.